Exact Mass: 315.1735

Exact Mass Matches: 315.1735

Found 172 metabolites which its exact mass value is equals to given mass value 315.1735, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Belladine

Belladine

C19H25NO3 (315.1834)


A phenethylamine alkaloid that is N-methyl-4-methoxyphenylethylamine carrying an additional N-(3,4-dimethoxybenzyl) substituent.

   

Alizapride

6-methoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-2H-1,2,3-benzotriazole-5-carboxamide

C16H21N5O2 (315.1695)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents

   

(E)-Piperolein A

(6E)-7-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one

C19H25NO3 (315.1834)


(e)-piperolein a is a member of the class of compounds known as benzodioxoles. Benzodioxoles are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms (e)-piperolein a is practically insoluble (in water) and an extremely weak basic (essentially neutral) compound (based on its pKa). (e)-piperolein a can be found in herbs and spices, which makes (e)-piperolein a a potential biomarker for the consumption of this food product. (E)-Piperolein A is found in herbs and spices. (E)-Piperolein A is a minor constituent of Piper nigrum (pepper

   

Mitiglinide

Calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate

C19H25NO3 (315.1834)


Mitiglinide is only found in individuals that have used or taken this drug. It is a drug for the treatment of type 2 diabetes.Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.

   

Alizapride

6-methoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-2H-1,2,3-benzotriazole-5-carboxamide

C16H21N5O2 (315.1695)


Alizapride is only found in individuals that have used or taken this drug. It is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)—this action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other atributres related to emesis and prokinetics. D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents

   

Rotigotine

6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol

C19H25NOS (315.1657)


Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinsons disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998, Aderis licensed worldwide development and commercialization rights for rotigotine to the German pharmaceutical company Schwarz Pharma (today a subsidiary of the Belgian company UCB S.A.). The drug has been approved by the EMEA for use in Europe in 2006 and is today being sold in several European countries. In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal treatment of Parkinsons disease in the United States. However, as of 2008, Schwarz Pharma has recalled all Neupro patches in the United States and some in Europe because of problems with the delivery mechanism. Rotigotine has been authorized as a treatment for RLS since August 2008. D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

(6Z)-Oct-6-enedioylcarnitine

3-[(7-carboxyhept-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO6 (315.1682)


(6Z)-oct-6-enedioylcarnitine is an acylcarnitine. More specifically, it is an (6Z)-oct-6-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z)-oct-6-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6Z)-oct-6-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Oct-4-enedioylcarnitine

3-[(7-carboxyhept-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO6 (315.1682)


oct-4-enedioylcarnitine is an acylcarnitine. More specifically, it is an oct-4-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. oct-4-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine oct-4-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Oct-5-enedioylcarnitine

3-[(7-carboxyhept-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO6 (315.1682)


oct-5-enedioylcarnitine is an acylcarnitine. More specifically, it is an oct-5-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. oct-5-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine oct-5-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E)-Oct-2-enedioylcarnitine

3-[(7-carboxyhept-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H25NO6 (315.1682)


(2E)-oct-2-enedioylcarnitine is an acylcarnitine. More specifically, it is an (2E)-oct-2-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-oct-2-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E)-oct-2-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dihydroethidium

5-ethyl-6-phenyl-5,6-dihydrophenanthridine-3,8-diamine

C21H21N3 (315.1735)


   

Indicine-N-oxide

7-({[2,3-dihydroxy-2-(propan-2-yl)butanoyl]oxy}methyl)-1-hydroxy-1,2,3,4,5,7a-hexahydropyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

Indicine N-oxide

Indicine N-oxide

C15H25NO6 (315.1682)


   
   

(E)-(4-Hydroxycinnamoyl)-epilupinine

(E)-(4-Hydroxycinnamoyl)-epilupinine

C19H25NO3 (315.1834)


   
   

1-Carboxytrypargine

1-Carboxytrypargine

C16H21N5O2 (315.1695)


   

(Z)-(4-Hydroxycinnamoyl)-epilupinine

(Z)-(4-Hydroxycinnamoyl)-epilupinine

C19H25NO3 (315.1834)


   

Lupinyl trans-p-coumarate

(-)-(trans-4-Hydroxycinnamoyl)lupinine

C19H25NO3 (315.1834)


   
   

1-(3,4-Dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)propan-2-amine

1-(3,4-Dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)propan-2-amine

C19H25NO3 (315.1834)


   

SCHEMBL1478023

SCHEMBL1478023

C19H25NO3 (315.1834)


   

Me ether- Dihydroerysodine

Me ether- Dihydroerysodine

C19H25NO3 (315.1834)


   

(-)-(trans-4-Hydroxycinnamoyl)lupinine

(-)-(trans-4-Hydroxycinnamoyl)lupinine

C19H25NO3 (315.1834)


   

trans-3-isobutyl-4-[4-(3-methyl-3-butenyloxy)phenyl]pyrrolidine-2,5-dione

trans-3-isobutyl-4-[4-(3-methyl-3-butenyloxy)phenyl]pyrrolidine-2,5-dione

C19H25NO3 (315.1834)


   

1-Methoxy-2-hydroxy-schelhammericine

1-Methoxy-2-hydroxy-schelhammericine

C19H25NO3 (315.1834)


   

2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoic acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester|leptanthine

2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoic acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester|leptanthine

C15H25NO6 (315.1682)


   

(14E)-solanapyrone O

(14E)-solanapyrone O

C19H25NO3 (315.1834)


   

solanapyrone L

solanapyrone L

C19H25NO3 (315.1834)


   

N-de(phenylethyl)isohericerin

N-de(phenylethyl)isohericerin

C19H25NO3 (315.1834)


   
   
   

(R)-3-(2-hydroxy-3-methoxy-3-methylbutyl)-5-(3-methyl-1-oxo-2-butenyl)indole

(R)-3-(2-hydroxy-3-methoxy-3-methylbutyl)-5-(3-methyl-1-oxo-2-butenyl)indole

C19H25NO3 (315.1834)


   

1-[(2E)-1-oxo-7-(3,4-methylenedioxy)phenylheptenyl]piperidine|piperine S

1-[(2E)-1-oxo-7-(3,4-methylenedioxy)phenylheptenyl]piperidine|piperine S

C19H25NO3 (315.1834)


   

Isocryprochine|isocryprocine

Isocryprochine|isocryprocine

C19H25NO3 (315.1834)


   

Isolucidinine

Isolucidinine

C19H25NO3 (315.1834)


   
   
   
   
   
   
   
   

NCI60_000712

Butanoic acid,3-dihydroxy-2-(1-methylethyl)- (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) methyl ester, N-oxide, (1R-(1.alpha.,7(2R*,3S*),7a.beta))-

C15H25NO6 (315.1682)


Indicine N-oxide is a natural product found in Tournefortia argentea with data available. Indicine-N-Oxide is a natural pyrrolizidine alkaloid with antineoplastic properties. Indicine-N-oxide alkylates and crosslinks DNA. (NCI04)

   

Rinderine N-oxide

[(7S,8R)-7-hydroxy-4-oxido-5,6,7,8-tetrahydro-3H-pyrrolizin-4-ium-1-yl]methyl (2S)-2-hydroxy-2-[(1R)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO6 (315.1682)


   

Echinatine oxide

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)- (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) methyl ester, N-oxide, (1R-(1.alpha.,7(2R*,3S*),7a.b.eta.))-

C15H25NO6 (315.1682)


   

Lycopsamine N-oxide

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl ester, N-oxide, [1R-[1?,7(2S*,3R*),7a?]]-; Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1-hydroxy-4-oxido-1H-pyrrolizin-7-yl)methyl ester, [1R-[1?,7(2S*,3R*),7a?]]-; Intermedine N-oxide

C15H25NO6 (315.1682)


Lycopsamine N-oxide is a natural product found in Symphytum officinale, Neatostema apulum, and Idea leuconoe with data available.

   
   

Intermedine N-oxide

Intermedine N-oxide

C15H25NO6 (315.1682)


CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2272

   

Lycopsamine N-oxide

Lycopsamine N-oxide

C15H25NO6 (315.1682)


CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2294

   

Nonyltyrazolone

Nonyltyrazolone

C19H25NO3 (315.1834)


   
   
   
   

Dehydroxyoxitropium

Dehydroxyoxitropium

C19H25NO3 (315.1834)


   
   
   
   

Pentazocine trans acid

Pentazocine trans acid

C19H25NO3 (315.1834)


   
   
   
   
   
   
   

3-O-Methyldobutamine

3-O-Methyldobutamine

C19H25NO3 (315.1834)


   

Mitiglinide

2-benzyl-4-(octahydro-1H-isoindol-2-yl)-4-oxobutanoic acid

C19H25NO3 (315.1834)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents

   

Rotigotine

6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol

C19H25NOS (315.1657)


N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71?nM, 4-15?nM, and 83?nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research[1][2][3][4].

   

(E)-Piperolein A

(6E)-7-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one

C19H25NO3 (315.1834)


   

1,3,5-Triazine,hexahydro-1,3,5-triphenyl-

1,3,5-Triazine,hexahydro-1,3,5-triphenyl-

C21H21N3 (315.1735)


   

1-BENZYL-2-(2-(1-METHYL-1H-PYRROL-2-YL)ETHYL)-1H-BENZO[D]IMIDAZOLE

1-BENZYL-2-(2-(1-METHYL-1H-PYRROL-2-YL)ETHYL)-1H-BENZO[D]IMIDAZOLE

C21H21N3 (315.1735)


   

2-ethylhexyl dihydrogen phosphate,2-(2-hydroxyethylamino)ethanol

2-ethylhexyl dihydrogen phosphate,2-(2-hydroxyethylamino)ethanol

C12H30NO6P (315.1811)


   

1-(3,3-diphenylpropyl)piperidinium chloride

1-(3,3-diphenylpropyl)piperidinium chloride

C20H26ClN (315.1754)


   

Dopamantine

Dopamantinum [INN-Latin]

C19H25NO3 (315.1834)


C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

N-BOC-AMINO-(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETICACID

N-BOC-AMINO-(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-ACETICACID

C15H25NO6 (315.1682)


   

DIETHYL 2-(1-(TERT-BUTOXYCARBONYL)AZETIDIN-3-YL)MALONATE

DIETHYL 2-(1-(TERT-BUTOXYCARBONYL)AZETIDIN-3-YL)MALONATE

C15H25NO6 (315.1682)


   

Boc-L-aspartic acid 4-cyclohexyl ester

Boc-L-aspartic acid 4-cyclohexyl ester

C15H25NO6 (315.1682)


   

4-(DIMETHYLAMINO)BENZALDEHYDE DIPHENYLHYDRAZONE

4-(DIMETHYLAMINO)BENZALDEHYDE DIPHENYLHYDRAZONE

C21H21N3 (315.1735)


   

Dihydroethidium

Dihydroethidium

C21H21N3 (315.1735)


   

6-[propyl(2-thiophen-3-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol

6-[propyl(2-thiophen-3-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol

C19H25NOS (315.1657)


   

Boc-D-Asp(OcHex)-OH

Boc-D-Asp(OcHex)-OH

C15H25NO6 (315.1682)


   

dibutyl hydrogen phosphate, compound with 2,2-iminodiethanol (1:1)

dibutyl hydrogen phosphate, compound with 2,2-iminodiethanol (1:1)

C12H30NO6P (315.1811)


   

Ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate

Ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate

C17H22BNO4 (315.1642)


   

R-Mitiglinide Calcium

R-Mitiglinide Calcium

C19H25NO3 (315.1834)


   

2-(3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)propyl)isoindoline-1,3-dione

2-(3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)propyl)isoindoline-1,3-dione

C17H22BNO4 (315.1642)


   

5-Amino-1-Boc-3,4,5,6-tetrahydro-2H-[2,4]bipyridinyl hydrochloride

5-Amino-1-Boc-3,4,5,6-tetrahydro-2H-[2,4]bipyridinyl hydrochloride

C15H26ClN3O2 (315.1713)


   

Tert-Butyl 5-Methyl-3-Oxo-2,3-Dihydrospiro[Indene-1,4-Piperidine]-1-Carboxylate

Tert-Butyl 5-Methyl-3-Oxo-2,3-Dihydrospiro[Indene-1,4-Piperidine]-1-Carboxylate

C19H25NO3 (315.1834)


   

TERT-BUTYL 4-OXO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

TERT-BUTYL 4-OXO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

C19H25NO3 (315.1834)


   

L-Leucine, L-seryl-L-prolyl-

L-Leucine, L-seryl-L-prolyl-

C14H25N3O5 (315.1794)


   

4,4-[(4-Iminocyclohexa-2,5-dien-1-ylidene)methylene]bis(2-methylaniline)

4,4-[(4-Iminocyclohexa-2,5-dien-1-ylidene)methylene]bis(2-methylaniline)

C21H21N3 (315.1735)


   

Oct-4-enedioylcarnitine

Oct-4-enedioylcarnitine

C15H25NO6 (315.1682)


   

Oct-5-enedioylcarnitine

Oct-5-enedioylcarnitine

C15H25NO6 (315.1682)


   

(6Z)-Oct-6-enedioylcarnitine

(6Z)-Oct-6-enedioylcarnitine

C15H25NO6 (315.1682)


   

(2E)-Oct-2-enedioylcarnitine

(2E)-Oct-2-enedioylcarnitine

C15H25NO6 (315.1682)


   

Aculene A

Aculene A

C19H25NO3 (315.1834)


A carboxylic ester resulting from the formal condensation of the hydroxy group of aculene C with the carboxylic acid group of L-proline. It is a sesquiterpenoid isolated from the fungus Aspergillus aculeatus.

   
   

N-(4-fluorophenyl)-6-methyl-1-propyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide

N-(4-fluorophenyl)-6-methyl-1-propyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxamide

C18H22FN3O (315.1747)


   

(1R,5S)-6-[[5-(2-fluoro-4-methoxyphenyl)-1H-pyrazol-4-yl]methyl]-6-azabicyclo[3.2.1]octane

(1R,5S)-6-[[5-(2-fluoro-4-methoxyphenyl)-1H-pyrazol-4-yl]methyl]-6-azabicyclo[3.2.1]octane

C18H22FN3O (315.1747)


   

(5-Methyl-1,2-oxazol-3-yl)-[4-(5-propylpyrimidin-2-yl)piperazin-1-yl]methanone

(5-Methyl-1,2-oxazol-3-yl)-[4-(5-propylpyrimidin-2-yl)piperazin-1-yl]methanone

C16H21N5O2 (315.1695)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(2E)-7-carboxyhept-2-enoylcarnitine

(2E)-7-carboxyhept-2-enoylcarnitine

C15H25NO6 (315.1682)


An O-acylcarnitine having (2E)-7-carboxyhept-2-enoyl as the acyl substituent.

   

(2E)-10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dec-2-enoate

(2E)-10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]dec-2-enoate

C16H27O6- (315.1808)


   

(E,9R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydec-2-enoate

(E,9R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydec-2-enoate

C16H27O6- (315.1808)


   

N-Acetyl-alanyl-valyl-alanine methyl ester

N-Acetyl-alanyl-valyl-alanine methyl ester

C14H25N3O5 (315.1794)


   

N-Acetyl-alanyl-leucyl-glycine methylester

N-Acetyl-alanyl-leucyl-glycine methylester

C14H25N3O5 (315.1794)


   

N-Acetyl-glycyl-leucyl-alanine methylester

N-Acetyl-glycyl-leucyl-alanine methylester

C14H25N3O5 (315.1794)


   

(±)-Rotigotine

1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-

C19H25NOS (315.1657)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

oscr#15(1-)

oscr#15(1-)

C16H27O6 (315.1808)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#15, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#15(1-)

ascr#15(1-)

C16H27O6 (315.1808)


Conjugate base of ascr#15

   

O-octenedioylcarnitine

O-octenedioylcarnitine

C15H25NO6 (315.1682)


An O-acylcarnitine obtained by formal condensation of one of the carboxy groups of any octenedioic acid with the hydroxy group of carnitine.

   
   
   

1-[3-(2-hydroxy-3-methoxy-3-methylbutyl)-1h-indol-5-yl]-3-methylbut-2-en-1-one

1-[3-(2-hydroxy-3-methoxy-3-methylbutyl)-1h-indol-5-yl]-3-methylbut-2-en-1-one

C19H25NO3 (315.1834)


   

(1s,14r,17r)-5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-4-ol

(1s,14r,17r)-5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-4-ol

C19H25NO3 (315.1834)


   

(1r,7ar)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7ar)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

octahydro-1h-quinolizin-1-ylmethyl 3-(4-hydroxyphenyl)prop-2-enoate

octahydro-1h-quinolizin-1-ylmethyl 3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-2-en-1-one

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-2-en-1-one

C19H25NO3 (315.1834)


   

amuroline

NA

C19H25NO3 (315.1834)


{"Ingredient_id": "HBIN015930","Ingredient_name": "amuroline","Alias": "NA","Ingredient_formula": "C19H25NO3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1100","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s,17r)-4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-5-ol

(1s,17r)-4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-5-ol

C19H25NO3 (315.1834)


   

5-[3-(4-hydroxy-4-methylpent-2-en-1-yl)-3-methyloxiran-2-yl]-3-methyl-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

5-[3-(4-hydroxy-4-methylpent-2-en-1-yl)-3-methyloxiran-2-yl]-3-methyl-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

C19H25NO3 (315.1834)


   

5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-4-ol

5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-4-ol

C19H25NO3 (315.1834)


   

(1s,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1s,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(1r,2s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),3,8'(12'),9'-tetraen-2-ol

(1r,2s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),3,8'(12'),9'-tetraen-2-ol

C19H25NO3 (315.1834)


   

5-(3,7-dimethylocta-2,6-dien-1-yl)-6-methoxy-3h-isoindole-1,4-diol

5-(3,7-dimethylocta-2,6-dien-1-yl)-6-methoxy-3h-isoindole-1,4-diol

C19H25NO3 (315.1834)


   

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

C19H25NO3 (315.1834)


   

5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6-methoxy-3h-isoindole-1,4-diol

5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6-methoxy-3h-isoindole-1,4-diol

C19H25NO3 (315.1834)


   

(3ar,4s)-1-ethyl-3a,6-dimethyl-3-oxo-4,5-dihydroazulen-4-yl (2s)-pyrrolidine-2-carboxylate

(3ar,4s)-1-ethyl-3a,6-dimethyl-3-oxo-4,5-dihydroazulen-4-yl (2s)-pyrrolidine-2-carboxylate

C19H25NO3 (315.1834)


   

(1s,4r,4's)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

(1s,4r,4's)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

C19H25NO3 (315.1834)


   

5-hydroxy-3-{4-[(3-methylbut-3-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)-3,4-dihydropyrrol-2-one

5-hydroxy-3-{4-[(3-methylbut-3-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)-3,4-dihydropyrrol-2-one

C19H25NO3 (315.1834)


   

4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-5-ol

4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-5-ol

C19H25NO3 (315.1834)


   

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2z)-3-(4-hydroxyphenyl)prop-2-enoate

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2z)-3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

(1r)-1-(3-carbamimidamidopropyl)-2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid

(1r)-1-(3-carbamimidamidopropyl)-2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid

C16H21N5O2 (315.1695)


   

1-{3-[(2r)-2-hydroxy-3-methoxy-3-methylbutyl]-1h-indol-5-yl}-3-methylbut-2-en-1-one

1-{3-[(2r)-2-hydroxy-3-methoxy-3-methylbutyl]-1h-indol-5-yl}-3-methylbut-2-en-1-one

C19H25NO3 (315.1834)


   

(1r,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

(1r,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

3-hydroxy-4-methoxy-9-methyl-9-azapentacyclo[8.8.0.0¹,⁶.0²,¹³.0¹³,¹⁸]octadeca-5,14-dien-16-one

3-hydroxy-4-methoxy-9-methyl-9-azapentacyclo[8.8.0.0¹,⁶.0²,¹³.0¹³,¹⁸]octadeca-5,14-dien-16-one

C19H25NO3 (315.1834)


   

(1s,14r,17r)-4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-5-ol

(1s,14r,17r)-4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-5-ol

C19H25NO3 (315.1834)


   

1-ethyl-3a,6-dimethyl-3-oxo-4,5-dihydroazulen-4-yl pyrrolidine-2-carboxylate

1-ethyl-3a,6-dimethyl-3-oxo-4,5-dihydroazulen-4-yl pyrrolidine-2-carboxylate

C19H25NO3 (315.1834)


   

(1s,9as)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

(1s,9as)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-5-ol

4,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-5-ol

C19H25NO3 (315.1834)


   

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one

7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one

C19H25NO3 (315.1834)


   

5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-4-ol

5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,15-tetraen-4-ol

C19H25NO3 (315.1834)


   

(1r,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),3,8'(12'),9'-tetraen-2-ol

10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),3,8'(12'),9'-tetraen-2-ol

C19H25NO3 (315.1834)


   

(1s)-1-(3-carbamimidamidopropyl)-2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid

(1s)-1-(3-carbamimidamidopropyl)-2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid

C16H21N5O2 (315.1695)


   

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r)-2,3-dihydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoate

[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r)-2,3-dihydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO6 (315.1682)


   

(1s,4s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

(1s,4s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-ol

C19H25NO3 (315.1834)


   

(1s,17s)-5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-4-ol

(1s,17s)-5,17-dimethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraen-4-ol

C19H25NO3 (315.1834)


   

(2e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-2-en-1-one

(2e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hept-2-en-1-one

C19H25NO3 (315.1834)


   

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C19H25NO3 (315.1834)


   

(1s,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1s,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(2z,4e)-5-{3-[(2e)-4-hydroxy-4-methylpent-2-en-1-yl]-3-methyloxiran-2-yl}-3-methyl-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

(2z,4e)-5-{3-[(2e)-4-hydroxy-4-methylpent-2-en-1-yl]-3-methyloxiran-2-yl}-3-methyl-1-(1h-pyrrol-2-yl)penta-2,4-dien-1-one

C19H25NO3 (315.1834)


   

(1s,5r,13r,14r,17r)-10,14-dimethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene

(1s,5r,13r,14r,17r)-10,14-dimethoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-triene

C19H25NO3 (315.1834)


   

(1r,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7ar)-1-hydroxy-7-({[(2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(1r,4s,7ar)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,4s,7ar)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(1r,7as)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7as)-1-hydroxy-7-({[(2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-4-ium-4-olate

C15H25NO6 (315.1682)


   

(3s,4r)-5-hydroxy-3-{4-[(3-methylbut-3-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)-3,4-dihydropyrrol-2-one

(3s,4r)-5-hydroxy-3-{4-[(3-methylbut-3-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)-3,4-dihydropyrrol-2-one

C19H25NO3 (315.1834)